ORAGENICS, INC. Proceeds from Common Stock Issued
ORAGENICS, INC. (OGEN) reported Proceeds from Common Stock Issued of $79.21 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-13
- ORAGENICS, INC. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $0.00.
- ORAGENICS, INC. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $79.21K, a 96.99% decline year-over-year.
- ORAGENICS, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was -$1.14K, a 157.87% decline year-over-year.
- ORAGENICS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. proceeds from issuance of common stock for fiscal 2025 was $2.63M, a 60.52% decline from fiscal 2024.
- ORAGENICS, INC. proceeds from issuance of common stock for fiscal 2024 was $6.67M.
- ORAGENICS, INC. proceeds from issuance of common stock for fiscal 2022 was $69.29K, a 99.74% decline from fiscal 2021.
- ORAGENICS, INC. proceeds from issuance of common stock for fiscal 2021 was $26.68M, a 135.25% increase from fiscal 2020.
| Period end | Proceeds from Issuance of Common Stock 0 month | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $79.21K 10-Q · filed 2026-08-13 | $78.07K derived: sum of 3 quarters · filed 2026-08-13 | $78.07K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $79.21K 10-Q · filed 2026-05-08 | $78.07K derived: sum of 2 quarters · filed 2026-05-08 | $78.07K derived: sum of 3 quarters · filed 2026-05-08 | $78.07K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$1.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.14K derived: sum of 2 quarters · filed 2026-03-16 | -$1.14K derived: sum of 3 quarters · filed 2026-08-13 | $2.63M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $2.64M 10-Q · filed 2025-11-07 | $2.64M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.64M 10-Q · filed 2026-08-13 | $2.64M derived: sum of 3 quarters · filed 2026-08-13 | $6.52M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $2.64M 10-Q · filed 2026-05-08 | $2.64M derived: sum of 2 quarters · filed 2026-05-08 | $6.52M derived: sum of 3 quarters · filed 2026-05-08 | $7.47M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $1.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.89M derived: sum of 2 quarters · filed 2026-03-16 | $4.83M derived: sum of 3 quarters · filed 2026-03-16 | $6.67M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.83M derived: sum of 2 quarters · filed 2025-11-07 | $6.67M 10-Q · filed 2025-11-07 | ||||
| 2024-06-30 | $948.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $2.79M 10-Q · filed 2025-08-08 | |||||
| 2024-03-31 | $1.84M 10-Q · filed 2025-05-09 | ||||||
| 2023-09-30 | $849.81K 10-Q · filed 2024-11-13 | ||||||
| 2022-12-31 | $69.29K 10-K · filed 2023-04-17 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-04-17 | $0.00 derived: sum of 2 quarters · filed 2023-04-17 | $0.00 derived: sum of 3 quarters · filed 2023-04-17 | $26.68M 10-K · filed 2023-04-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2023-04-14 | $0.00 derived: sum of 2 quarters · filed 2023-04-14 | $26.68M 10-Q/A · filed 2023-04-14 | ||||
| 2021-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2023-04-14 | $26.68M 10-Q/A · filed 2023-04-14 | |||||
| 2021-03-31 | $26.68M 10-Q/A · filed 2023-04-14 | ||||||
| 2020-12-31 | $11.34M 10-K/A · filed 2022-07-29 | ||||||
| 2018-12-31 | $13.80M 10-K · filed 2019-03-29 | ||||||
| 2018-07-17 | $13.80M 10-K · filed 2019-03-29 | ||||||
| 2016-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $1.00 derived: sum of 2 quarters · filed 2018-02-16 | $2.64M 10-K · filed 2018-02-16 | ||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $2.64M 10-Q · filed 2017-10-31 | |||||
| 2016-06-30 | $2.64M 10-Q · filed 2017-08-14 | ||||||
| 2013-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $13.77M derived: sum of 2 quarters · filed 2015-02-27 | $13.80M 10-K · filed 2015-02-27 | ||||
| 2013-09-30 | $3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-03 | $3.94M 10-Q · filed 2014-11-03 | |||||
| 2013-06-30 | $30.00K 10-Q · filed 2014-08-07 | ||||||
| 2012-12-31 | $1.09M derived: 10-Q 12 month − 10-Q 9 month · filed 2014-11-03 | $13.00M 10-Q · filed 2014-11-03 | $11.89M 10-K · filed 2013-03-26 | ||||
| 2012-09-30 | $11.91M 10-Q · filed 2013-10-25 | ||||||
| 2012-07-31 | $13.00M 10-K · filed 2013-03-26 | ||||||
| 2012-07-30 | $13.00M 10-K · filed 2014-02-28 | $13.00M 10-Q · filed 2012-08-10 | |||||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-05 | ||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $1.00M derived: sum of 2 quarters · filed 2012-04-16 | $1.50M 10-K · filed 2012-04-16 | ||||
| 2010-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $1.50M 10-Q · filed 2011-11-14 | |||||
| 2010-06-30 | $500.00K 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |